Preoperative Capecitabine and Pelvic Radiation in Locally Advanced Rectal Cancer-Is it Equivalent to 5-FU Infusion Plus Leucovorin and Radiotherapy?
Purpose: The aim of this retrospective case-matching study was to compare the treatment outcomes and acute toxicity of preoperative radiotherapy (RT) with capecitabine vs. preoperative RT with intermittent 5-fluorouracil (5-FU) infusion, leucovorin, and mitomycin C in rectal cancer. Methods and Materials: We matched 34 patients who were treated with preoperative concurrent capecitabine and 50 Gy of RT by their clinical T stage (T3 or T4) and the tumor location (<=7 cm or >7 cm from the anal verge) with another 68 patients who were treated with preoperative intermittent 5-FU infusion, leucovorin, mitomycin C, and 50 Gy of RT for a comparison of the pathologic tumor response, local control, distant failure, and survival rates. Results: The pathologic complete response rate was 21% with capecitabine and 18% with 5-FU and leucovorin (p = 0.72). The rate of T downstaging after chemoradiation was 59% for both groups. The rate of sphincter-sparing resection was 38% after capecitabine plus RT and 43% after 5-FU plus RT (p = 0.67). At 3 years, there was no significant difference in the local control rate (93% for capecitabine and 92% for 5-FU and leucovorin), relapse-free rate (74% for capecitabine and 73% for 5-FU and leucovorin), or disease-specific survivalmore »
- Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Department of Surgery, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Publication Date:
- OSTI Identifier:
- Resource Type:
- Journal Article
- Resource Relation:
- Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 76; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2009.03.048; PII: S0360-3016(09)00517-3; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.
- Country of Publication:
- United States
- 62 RADIOLOGY AND NUCLEAR MEDICINE; CITROVORUM FACTOR; FLUOROURACILS; INFUSION; MITOMYCIN; NEOPLASMS; RADIOTHERAPY; RECTUM; TOXICITY ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTIMETABOLITES; ANTIMITOTIC DRUGS; ANTINEOPLASTIC DRUGS; AZINES; BODY; DIGESTIVE SYSTEM; DISEASES; DRUGS; GASTROINTESTINAL TRACT; HETEROCYCLIC COMPOUNDS; HYDROXY COMPOUNDS; INTAKE; INTESTINES; LARGE INTESTINE; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANIC FLUORINE COMPOUNDS; ORGANIC HALOGEN COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANS; PYRIMIDINES; RADIOLOGY; THERAPY; URACILS